Drug delivery system in treatment against inflammatory bowel disease: present and future

Satohiro Masuda, Yuki Yamamoto

Research output: Contribution to journalArticle

Abstract

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate anti-inflammatory drug used as a primary agent to treat inflammatory bowel disease, including ulcerative colitis and to maintain remission in Crohn’s disease. The efficacy of 5-ASA is determined by the degree of drug delivery to the site of inflammation, but it depends on the formulation. In recent years, 5-ASA preparations using drug-delivery system (DDS) technology as a therapeutic agent for ulcerative colitis have been developed one after another, contributing to improvement of therapeutic effect. In this article, we focus on the pharmacokinetic characteristics of each 5-ASA preparation, and introduce the features and clinical usefulness of the preparation.

Original languageEnglish
Pages (from-to)397-405
Number of pages9
JournalDrug Delivery System
Volume33
Issue number5
DOIs
Publication statusPublished - Nov 25 2018

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Drug delivery system in treatment against inflammatory bowel disease: present and future'. Together they form a unique fingerprint.

  • Cite this